Description
Natalizumab (Tysabri®) is a humanized monoclonal antibody against the cell adhesion molecule α4-integrin used in the treatment of multiple sclerosis and Crohn's disease. Tysabri® and was previously named Antegren®. Natalizumab is administered by intravenous infusion every 28 days and reduces the ability of inflammatory immune cells to attach to and pass through the cell layers lining the intestines and blood– brain barrier